Rethinking Success in Neuroscience Clinical Development

Despite significant scientific progress in neuroscience, clinical trial success rates remain low. Complex diseases, evolving therapeutic approaches and challenges around endpoint selection continue to make development difficult.

As biomarkers, AI and precision medicine become increasingly integrated into clinical research, sponsors have new opportunities to strengthen study design, improve patient selection and make more informed development decisions throughout the clinical development journey.

This podcast explores:
-Why endpoint selection remains one of the greatest challenges in neuroscience development
-How biomarkers are improving trial design and earlier development decisions
-The role of AI and precision medicine in advancing neuroscience research
-Common pitfalls when transitioning from early-phase to pivotal studies
-Why early regulatory engagement and integrated development strategies matter